Mitochondrial respiratory activity and DNA damage in peripheral blood mononuclear cells in borderline personality disorder
medRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 31, 2025
Abstract
Alterations
in
the
central
and
peripheral
energy
metabolism
are
increasingly
recognized
as
key
pathophysiological
processes
various
psychiatric
disorders.
This
case-control
study
investigates
mitochondrial
production
oxidative
DNA
damage
Borderline
Personality
Disorder
(BPD).
We
compared
respiration,
density,
blood
mononuclear
cells
between
women
with
acute
BPD,
remitted
healthy
controls
(
n
=
32,
15,
29),
matched
for
age
BMI.
Acute
BPD
was
characterized
by
reduced
less
efficient
ATP
to
both
(e.g.,
coupling
efficiency:
r
x
−0.36
−0.35,
p
adj
’s
<
.037).
Decreased
activity
closely
associated
greater
S
−0.57,
.001),
although
did
not
differ
diagnostic
groups.
Our
findings
suggest
promising
sensitive
biomarkers
disorder
severity
clinical
remission
BPD.
Язык: Английский
Ketogenic metabolic therapy for schizoaffective disorder: a retrospective case series of psychotic symptom remission and mood recovery
Frontiers in Nutrition,
Год журнала:
2025,
Номер
12
Опубликована: Фев. 7, 2025
Schizoaffective
disorder
is
a
severe
psychiatric
condition
characterized
by
mood
disturbances
and
psychotic
symptoms.
Standard
treatments,
primarily
pharmacological,
often
fail
to
control
symptoms
fully
can
lead
significant
metabolic
side
effects.
Emerging
evidence
suggests
that
ketogenic
therapy
(KMT),
also
known
as
the
diet,
may
offer
powerful
alternative
conventional
treatments
for
components
resolve
in
patients
with
schizoaffective
disorder.
This
case
series
investigates
effects
of
KMT
on
two
individuals
diagnosed
who
pursued
this
due
ineffectiveness
treatments.
Both
presentations
followed
modified
diet
medical
oversight.
Symptom
changes
were
assessed
using
validated
tools,
including
Generalized
Anxiety
Disorder-7
(GAD-7),
Depression
Stress
Scales
(DASS-42),
PTSD
Checklist
DSM-5
(PCL-5),
Patient
Health
Questionnaire-9
(PHQ-9).
experienced
complete
cessation
improvements
mood.
Case
1,
17-year-old
female,
achieved
full
remission
suicidal
ideation,
hallucinations,
anxiety
within
6
weeks,
sustained
at
24-week
follow-up.
2,
32-year-old
chronic
months.
Patients
either
deprescription
or
process
time
demonstrates
disorder,
leading
functional
recovery
reported
quality
life
extend
beyond
symptom
standard
care
interventions.
Язык: Английский
Treatments for weight gain in schizophrenia
Current Opinion in Psychiatry,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 13, 2025
Purpose
of
review
Obesity
and
related
metabolic
disorders
are
extremely
common
in
psychiatric
patients,
particularly
those
with
schizophrenia.
Elucidating
this
link's
neurobiology
may
inform
clinicians
researchers
rational
therapeutic
approaches
necessary
to
optimize
clinical
outcomes.
Recent
findings
Current
literature
highlights
the
pivotal
role
inflammation-oxidative
stress-insulin
resistance
loop
pathophysiology
both
neuropsychiatric
disorders.
The
concept
‘diabetophrenia’
is
put
forward
highlight
overlapping
neurobiological
mechanisms
underlying
dysfunction
schizophrenia
symptoms.
Innovative
treatments,
including
combination
xanomeline
trospium
incretin-based
medicines,
demonstrate
encouraging
potential
addressing
such
complex
health
challenges.
Summary
nuanced
dynamics
chronic
inflammation
symptomatology
underscore
significance
mental
factors
a
cohesive
fashion
while
considering
unique
psychosocial
contexts,
dietary
preferences,
lifestyle
choices.
A
multidisciplinary
strategy
essential
for
incorporating
counseling,
interventions,
behavioral
therapies,
pharmacotherapy
into
management
ensuing
enhanced
collaboration
among
healthcare
professionals
render
obsolete
prevailing
siloed
conceptualizations
disorders,
opening
new
vistas
generating
synergistic
insights
mind-body
systems
leading
improved
quality
life
patients
other
conditions.
Язык: Английский